BR112012014471A2 - método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam - Google Patents

método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam

Info

Publication number
BR112012014471A2
BR112012014471A2 BR112012014471A BR112012014471A BR112012014471A2 BR 112012014471 A2 BR112012014471 A2 BR 112012014471A2 BR 112012014471 A BR112012014471 A BR 112012014471A BR 112012014471 A BR112012014471 A BR 112012014471A BR 112012014471 A2 BR112012014471 A2 BR 112012014471A2
Authority
BR
Brazil
Prior art keywords
catenin
nefopam
disorders
cancer
compounds
Prior art date
Application number
BR112012014471A
Other languages
English (en)
Inventor
A Alman Benjamin
Hong Helen
Poon Raymond
Original Assignee
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44166687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012014471(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hospital For Sick Children filed Critical Hospital For Sick Children
Publication of BR112012014471A2 publication Critical patent/BR112012014471A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

método para o tratamento de cicatrizes e de desordens mediadas por beta-catenina usando compostos nefopam - a presente invenção refere-se a métodos para o tratamento de desordens mediadas por <225>-catenina compreendendo a administração de compostos nefopam. em particular, é contemplando o tratamento de desordens provenientes da expressão excessiva ou indesejável da <225>-catenina. tais compostos incluem o nefopam, análogos do mesmo, pró-fármaco do mesmo, sais ou solvatos do nefopam. as desordens medidas por <225>-catenina são preferivelmente selecionadas do grupo consisntindo de desordens fibroproliferativas (tais como cicatrizes, fibromatoses agressivas e fibroses) e câncer (tais como câncer do cólon, melanoma, câncer hepático, câncer ovariano, câncer endometrial, meduloblastoma, pilomatricomas e câncer de próstata).
BR112012014471A 2009-12-15 2010-12-15 método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam BR112012014471A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28663309P 2009-12-15 2009-12-15
PCT/CA2010/002014 WO2011072394A1 (en) 2009-12-15 2010-12-15 METHOD OF TREATING SCARS AND ß-CATENIN-MEDIATED DISORDERS USING NEFOPAM COMPOUNDS

Publications (1)

Publication Number Publication Date
BR112012014471A2 true BR112012014471A2 (pt) 2017-06-06

Family

ID=44166687

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014471A BR112012014471A2 (pt) 2009-12-15 2010-12-15 método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam

Country Status (11)

Country Link
US (4) US8957107B2 (pt)
EP (1) EP2512468B1 (pt)
JP (1) JP5792185B2 (pt)
KR (1) KR101753439B1 (pt)
CN (2) CN102781442B (pt)
BR (1) BR112012014471A2 (pt)
CA (1) CA2782472C (pt)
DK (1) DK2512468T3 (pt)
ES (1) ES2594900T3 (pt)
HK (2) HK1174565A1 (pt)
WO (1) WO2011072394A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012014471A2 (pt) * 2009-12-15 2017-06-06 Hospital For Sick Children método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
CA3065318A1 (en) * 2017-06-02 2018-12-06 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN112752574B (zh) * 2018-06-01 2024-02-09 伊特里恩治疗有限公司 特加维因和相关化合物的制剂
CN110638780A (zh) * 2019-09-11 2020-01-03 华益药业科技(安徽)有限公司 一种盐酸奈福泮片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
US20060019940A1 (en) 2002-12-20 2006-01-26 Baxter Andrew D Novel benzoxazocines and their therapeutic use
EP1950206A1 (en) 2002-12-20 2008-07-30 Sosei R&D Ltd. Benzoxazocines and their use as monoamine-reuptake inhibitors
GB0330049D0 (en) 2003-12-24 2004-02-04 Arakis Ltd The treatment of neuropathic pain conditions
WO2005103019A1 (en) 2004-04-21 2005-11-03 Sosei R&D Ltd. Benzoxazocines and their therapeutic use as monoamine reuptake inhibitors
GB2413322A (en) 2004-04-21 2005-10-26 Arakis Ltd Nefopam analogues
CN1569004A (zh) * 2004-05-13 2005-01-26 南昌弘益科技有限公司 盐酸奈福泮滴丸及其制备方法
FR2880275B1 (fr) 2005-01-06 2007-04-13 Biocodex Utilisation de composes pharmacologiques pour la prevention ou le traitement de la tolerance aigue aux morphiniques
GB0506835D0 (en) * 2005-04-04 2005-05-11 Arakis Ltd Therapeutic use of nefopam
GB0515703D0 (en) 2005-07-29 2005-09-07 Arakis Ltd Therapeutic use of nefopam
CN101002756A (zh) 2007-01-19 2007-07-25 陶燃 盐酸奈福泮的透皮贴片制剂
GB0721013D0 (en) 2007-10-25 2007-12-05 Sosei R & D Ltd New Salts
AU2009271411B2 (en) 2008-06-16 2013-02-07 Academia Sinica Cancer diagnosis based on levels of antibodies against Globo H and its fragments
GB2461874B (en) 2008-07-14 2012-11-21 Caltec Ltd Separation system and method
FR2940911B1 (fr) * 2009-01-13 2012-09-21 Philippe Perovitch Formulation pour l'administration par voie trans-muqueuse buccale de molecules antalgiques et/ou anti-spasmodiques
BR112012014471A2 (pt) * 2009-12-15 2017-06-06 Hospital For Sick Children método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam

Also Published As

Publication number Publication date
HK1174565A1 (zh) 2013-06-14
KR20120110117A (ko) 2012-10-09
US8957107B2 (en) 2015-02-17
CN102781442B (zh) 2016-02-17
CN105687185A (zh) 2016-06-22
US20120294928A1 (en) 2012-11-22
CN102781442A (zh) 2012-11-14
CN105687185B (zh) 2019-07-09
CA2782472A1 (en) 2011-06-23
JP5792185B2 (ja) 2015-10-07
EP2512468B1 (en) 2016-08-24
US20170172980A1 (en) 2017-06-22
EP2512468A1 (en) 2012-10-24
KR101753439B1 (ko) 2017-07-19
US20150105363A1 (en) 2015-04-16
US10722493B2 (en) 2020-07-28
DK2512468T3 (en) 2016-11-14
CA2782472C (en) 2019-04-16
US20170281594A1 (en) 2017-10-05
HK1224224A1 (zh) 2017-08-18
EP2512468A4 (en) 2013-08-07
ES2594900T3 (es) 2016-12-23
JP2013513625A (ja) 2013-04-22
WO2011072394A1 (en) 2011-06-23
US9566263B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
BR112012014471A2 (pt) método para o tratamento de cicatrizes e de distúrbios mediados por beta-catenina usando compostos nefopam
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
BR112015022998A2 (pt) composições melhoradas para o tratamento de distrofia muscular
CY1120617T1 (el) 1,2,5-οξαδιαζολια ως αναστολεις 2,3-διοξυγενασης ινδολοαμινης
PH12015501464A1 (en) Histone demethylase inhibitors
BR112015023038A2 (pt) composições para salto de exon para o tratamento da distrofia muscular
MX340402B (es) Inhibidores triciclicos de cinasas.
EA201492123A1 (ru) Композиции и способы для модулирования экспрессии семейства генов smn
ECSP14013223A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek
GEP20146138B (en) Method for treating androgen receptor positive cancers
MX367389B (es) Compuestos y sus metodos de empleo.
EA201100879A1 (ru) Производные пиридопиримидина в качестве ингибиторов аутотаксина
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
BR112012011195A2 (pt) Oligonucleotídeo antissentido, composição e respectivo uso.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
MX341877B (es) Compuestos y métodos para tratar influenza.
MX2015015144A (es) Potenciador de inhibidores del homologo de zeste.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
PH12016501048A1 (en) Piperidine derivatives as mdm2 inhibitors for the treatment of cancer
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
WO2012006181A3 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
EA201400245A1 (ru) Ингибиторы dyrk1 и их применение
BR112015011148A8 (pt) composto, composição farmacêutica, e combinação
EA201390015A1 (ru) Композиции и способы ингибирования пути jak

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements